Lexicon price target lowered to $36 from $42 at Wedbush
Wedbush analyst Liana Moussatos lowered her price target for Lexicon to $36 from $42, while reiterating an Outperform rating on the shares as she sees the split AdComm selloff "overdone." On January 17, the Endocrinologic and Metabolic Drug Advisory Committee had a split vote for/against approval of sotagliflozin as potentially the first oral antidiabetic drug used as an adjunct to insulin to improve glycemic control in adults with type 1 diabetes, she notes. The analyst points out that this was the first AdComm for an oral medication for T1D and the non-diabetes experts may have been thinking about T2D A1c drops not on insulin when criticizing the clinical meaningfulness of the 0.2%-0.4% placebo adjusted A1c drop for sotagliflozin. Moussatos also believes the DKA safety issue was "blown out of proportion." Even if FDA issues a CRL on March 22nd to allow more time to develop a RMS or even REMS, the analyst anticipates approval.